Transcriptional determinants of tolerogenic and immunogenic states during dendritic cell maturation

Dendritic cells (DCs) promote either tolerogenic or immunogenic T cell responses, the latter upon sensing microbes. Using an in vitro system, we analyzed transcriptional determinants that enable mature DCs to direct these opposing T cell outcomes. In the absence of microbial products, the transcript...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of cell biology Vol. 216; no. 3; pp. 779 - 792
Main Authors Vander Lugt, Bryan, Riddell, Jeremy, Khan, Aly A, Hackney, Jason A, Lesch, Justin, DeVoss, Jason, Weirauch, Matthew T, Singh, Harinder, Mellman, Ira
Format Journal Article
LanguageEnglish
Published United States Rockefeller University Press 06.03.2017
The Rockefeller University Press
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Dendritic cells (DCs) promote either tolerogenic or immunogenic T cell responses, the latter upon sensing microbes. Using an in vitro system, we analyzed transcriptional determinants that enable mature DCs to direct these opposing T cell outcomes. In the absence of microbial products, the transcription factor interferon regulatory factor 4 (IRF4) promotes regulatory T cell (T ) generation by enhancing expression of genes required for antigen presentation along with those for T cell tolerance. IRF4-deficient DCs were impaired for T generation in vivo. When exposed to microbial stimuli, DCs activated nuclear factor (NF)-κB, which induced expression of a proinflammatory cytokine module that, along with the antigen presentation module, promoted the generation of effector T cells. NF-κB was, however, dispensable for T development. Chromatin profiling revealed transcriptional motifs associated with the divergent DC programs. Thus, DCs modulate their ability to prime tolerogenic or immunogenic T cells by expressing a core antigen presentation module that is overlaid by distinctive regulatory modules to promote either tolerance or immunity.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
B. Vander Lugt’s, J. Lesch’s, and J. DeVoss’ present address is Dept. of Discovery Inflammation, Amgen, South San Francisco, CA 94080.
ISSN:0021-9525
1540-8140
DOI:10.1083/jcb.201512012